簡易檢索 / 詳目顯示

研究生: 黃渝珊
Huang, Yu-Shan
論文名稱: 探討Lunasin及Aspirin的處理對脂肪細胞與乳癌細胞發炎與生長之影響
The effects of lunasin, aspirin, and their combination on the inflammation and growth in adipocyte and breast cancer cell
指導教授: 謝佳倩
Hsieh, Chia-Chien
學位類別: 碩士
Master
系所名稱: 人類發展與家庭學系
Department of Human Development and Family Studies
論文出版年: 2015
畢業學年度: 103
語文別: 中文
論文頁數: 102
中文關鍵詞: LunasinAspirin肥胖乳癌發炎反應
英文關鍵詞: Lunasin, Aspirin, adipocytes, breast cancer, inflammation
論文種類: 學術論文
相關次數: 點閱:233下載:2
分享至:
查詢本校圖書館目錄 查詢臺灣博碩士論文知識加值系統 勘誤回報

乳癌為女性最常見的惡性腫瘤之一,肥胖者乳房脂肪組織中會有免疫細胞的浸潤伴隨著發炎性細胞激素的分泌,營造了適合腫瘤生長的微環境。Lunasin為43個胺基酸所組成的天然種子胜肽,已在細胞和動物實驗顯示具有效的癌症化學預防作用。Aspirin為使用已久的非固醇類抗發炎藥物,也被證實具有癌症預防作用,然而aspirin具有腸胃道副作用,因此近來許多研究使用aspirin合併其他具有癌症預防潛力的物質,期望降低其副作用並協同達到更好的抗癌效果。Lunasin及aspirin對於腫瘤微環境中脂肪細胞與乳癌細胞的交互影響仍然未知,因此,本研究欲探討lunasin、aspirin或兩者合併處理能否抑制脂肪細胞的發炎反應、脂肪與乳癌細胞間的交互作用,進而抑制乳癌細胞的生長。結果顯示,lunasin的處理能顯著降低TNF-α誘發3T3-L1脂肪細胞IL-6與MCP-1的分泌,而aspirin的處理能降低脂肪細胞在巨噬細胞條件培養液培養下其IL-6與MCP-1的分泌。對於4T1乳癌細胞,aspirin的處理顯著具有細胞毒殺作用,並抑制MCP-1與VEGF的分泌。而lunasin、aspirin或兩者共同處理,有劑量效應地抑制4T1細胞的移行能力。在3T3-L1脂肪細胞條件培養液培養4T1細胞實驗中,證實隨著脂肪細胞培養液比例的增加,顯著刺激4T1細胞生長,而aspirin的處理能顯著抑制脂肪細胞所刺激的乳癌細胞增生和MCP-1與PAI-1的分泌。另外,建立3T3-L1與4T1細胞經通透膜共培養模式,來模擬脂肪細胞存在的腫瘤微環境,結果顯示aspirin可有效地抑制4T1細胞生長及MCP-1與PAI-1的分泌,而lunasin能增強aspirin抑制4T1細胞生長的效果。綜合而論,lunasin能降低3T3-L1脂肪細胞IL-6與MCP-1的分泌、抑制4T1乳癌細胞的移行能力,並增強aspirin在脂肪細胞存在下抑制4T1細胞生長的效果。而Aspirin分別有效降低脂肪細胞與乳癌細胞其IL-6、MCP-1、VEGF與PAI-1的分泌,並抑制乳癌細胞生長與移行能力,在共培養模式中調控腫瘤微環境中細胞激素的分泌,進而抑制乳癌細胞的增生。Aspirin或合併lunasin使用可能有助於乳癌患者的輔助治療,作為日常飲食的建議,其相關機轉值得進一步研究探討。

Breast cancer is one of the most common cancers in women worldwide. The obese process normally accompanies chronic and low grade inflammation. Inflammatory cytokines secretion and immune cells infiltration provide a favorable microenvironment for tumor growth, migration, and metastasis. Lunasin is a seeds peptide with 43-amino acids has been demonstrated its chemopreventive properties in many cancers. Aspirin is another chemopreventive agent has been shown against several types of cancer, but complicated gastrointestinal injury simultaneously. Recently, some studies used aspirin combined with other chemopreventive compounds to reduce its side effects, and achieve synergistic effects. The aim of this work is to investigate the anti-inflammatory and anti-cancer properties of lunasin, aspirin and their combination on 3T3-L1 adipocytes, 4T1 murine breast cancer cells and their cross-talk using co-culture system. The results were showed that lunasin and aspirin significantly inhibited IL-6 and MCP-1 productions in adipocytes induced by TNF-α and RAW 264.7 cells conditioned-medium. In 4T1 breast cancer cells, aspirin has significantly cellular cytotoxicity effect, but lunasin didn’t affect cell growth on 4T1 cells. In wound healing assay, treatments of lunasin, aspirin and their combination inhibited 4T1 cell migration. Futhermore, aspirin inhibited cytokine MCP-1, VEGF and PAI-1 secretions of 4T1 cell cultured with adipocytes conditioned-medium and then inhibited 4T1 cell growth. In co-culture system, aspirin exerted the inhibitory effects as well as in conditioned-medim model. In additional, lunasin treatment enhanced aspirin’s cytotoxicity effect on 4T1 in this system. Summary, lunasin and aspirin inhibited inflammatory cytokines productions of 3T3-L1 adipocytes, migration of 4T1 cells and cross-talk between these cells, might contribute to their chemopreventive properties on 4T1 breast cancer cells. This study indicated the potential application of lunasin and/or combined with aspirin in the auxiliary therapy of obese relative breast cancer, and more experiments should be carried out in the future.

第一章 文獻探討 1 第一節 肥胖 1 一、 肥胖流行病學 1 二、 肥胖的發炎反應 2 三、 肥胖與腫瘤生成 3 1. Leptin 4 2. Adiponectin 5 3. VEGF (vascular endothelial growth factor) 6 4. PAI-1 (plasminogen activator inhibitor-1) 7 第二節 乳癌 8 一、 乳癌流行病學 8 二、 乳癌危險因子 8 三、 乳癌的分期與治療 9 四、 癌症的化學預防 (cancer chemoprevention) 10 第三節 Lunasin 13 一、 Lunasin簡介 13 二、 Lunasin降低膽固醇的作用 14 三、 Lunasin的抗發炎作用 14 四、 Lunasin的抗癌作用 15 第四節 Aspirin 16 一、 Aspirin簡介 16 二、 Aspirin的抗發炎作用 16 三、 Aspirin的抗癌作用 17 四、 Aspirin的副作用 18 五、 Aspirin合併其他物質的作用 19 第五節 研究工具 20 一、 3T3-L1脂肪細胞 20 二、 4T1乳癌細胞株 20 三、 脂肪細胞與乳癌細胞共培養的研究模式 21 第二章 研究假說與目的 22 第一節 研究假說 22 第二節 研究目的 23 第三節 實驗架構 24 第三章 實驗材料與方法 25 第一節 實驗樣品來源 25 第二節 實驗細胞來源 25 第三節 實驗儀器設備與耗材 25 第四節 實驗材料與方法 27 一、 3T3-L1脂肪細胞的培養與發炎反應的誘發 27 1. 細胞培養 27 2. MTT細胞存活率測定 28 3. 3T3-L1細胞分化 29 4. 油滴染色實驗 30 5. 以TNF-α刺激3T3-L1脂肪細胞產生發炎反應 31 6. 3T3-L1脂肪細胞與RAW264.7巨噬細胞條件培養液的共培養模式 32 7. 酵素連結免疫吸附分析 (ELISA) 33 二、 以4T1細胞株探討乳癌細胞的生長與轉移 34 1. 細胞培養 34 2. MTT細胞存活率測定 34 3. 4T1細胞移行試驗 (scratch wound healing assay) 34 4. 4T1細胞週期試驗 35 5. 4T1細胞激素測定 35 三、 建立3T3-L1脂肪細胞與4T1乳癌細胞的共培養模式 36 1. Leptin刺激4T1乳癌細胞生長 36 2. 3T3-L1脂肪細胞條件培養液培養4T1乳癌細胞之模式 37 3. 3T3-L1脂肪細胞與4T1乳癌細胞經由通透膜共培養模式 38 第五節 統計分析 39 第四章 實驗結果 40 第一節 以3T3-L1脂肪細胞探討肥胖相關的發炎反應 40 一、 Lunasin、aspirin或兩者共同處理對3T3-L1細胞存活率的影響 40 二、 Lunasin、aspirin或兩者共同處理對3T3-L1脂肪細胞的分化過程及脂質堆積作用的影響 41 三、 Lunasin對TNF-α刺激3T3-L1脂肪細胞發炎反應之影響 42 四、 Lunasin、aspirin或兩者共同處理對3T3-L1培養在RAW264.7條件培養液下對細胞激素分泌的影響 46 第二節 以4T1細胞株探討乳癌細胞的生長與轉移 50 一、 Lunasin、aspirin或兩者共同處理對4T1乳癌細胞存活率的影響 50 二、 Lunasin、aspirin或兩者共同處理對4T1乳癌細胞移行能力的影響 50 三、 4T1乳癌細胞之細胞週期 53 四、 Lunasin、aspirin或兩者共同處理對4T1細胞分泌之細胞激素的影響 55 第三節 3T3-L1與4T1的共培養模式 58 一、 Leptin對於4T1乳癌細胞生長的影響 58 二、 4T1乳癌細胞與3T3-L1脂肪細胞條件培養液共培養的模式 59 1. 建立模式 59 2. 3T3-Adipo-CM 模式下,lunasin、aspirin或兩者共同處理對於4T1乳癌細胞生長的影響 61 3. 3T3-Adipo-CM 模式下,lunasin、aspirin或兩者共同處理對於4T1乳癌細胞分泌之細胞激素的影響 63 三、 4T1乳癌細胞與3T3-L1脂肪細胞之通透膜共培養的模式 73 1. 在4T1與3T3-L1細胞共培養模式下,lunasin、aspirin或兩者共同處理在對於4T1乳癌細胞生長的影響 73 2. 在4T1與3T3-L1細胞共培養的模式下,lunasin、aspirin或兩者共同處理對細胞激素的影響 75 第五章 討論 78 第一節 以3T3-L1脂肪細胞探討肥胖相關的發炎反應 78 一、 Lunasin、aspirin或兩者共同處理對3T3-L1脂肪細胞的分化過程及脂質堆積作用的影響 78 二、 Lunasin、Aspirin或兩者共同處理對TNF-α/RAW-CM刺激3T3-L1脂肪細胞發炎反應之影響 79 第二節 以4T1細胞株探討乳癌細胞生長、移行能力及細胞激素的分泌 80 一、 Lunasin、Aspirin或兩者共同處理對4T1小鼠乳癌細胞生長與移行能力的影響 80 二、 Lunasin、Aspirin或兩者共同處理對4T1小鼠乳癌細胞分泌之細胞激素的影響 81 第三節 建立3T3-L1脂肪細胞與4T1乳癌細胞的共培養模式 83 一、 Leptin刺激4T1乳癌細胞生長 83 二、 3T3-L1脂肪細胞條件培養液培養4T1乳癌細胞之模式 84 三、 3T3-L1脂肪細胞與4T1乳癌細胞共培養模式 86 第六章 結論 87 第七章 參考文獻 89

Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab. 2000;11(8):327-32.
Ahn J, Schatzkin A, Lacey JV Jr, Albanes D, Ballard-Barbash R, Adams KF, et al. Adiposity, adult weight change, and postmenopausal breast cancer risk. Arch Intern Med. 2007;167(19):2091-102.
Amadou A, Torres Mejia G, Fagherazzi G, Ortega C, Angeles-Llerenas A, Chajes V, et al. Am J Prev Med. 2014;46(3 Suppl 1):S52-64.
Amann R, Peskar BA. Anti-inflammatory effects of aspirin and sodium salicylate. Eur J Pharmacol. 2002;447(1):1-9.
An Y, Liu K, Zhou Y, Liu B. Salicylate inhibits macrophage-secreted factors induced adipocyte inflammation and changes of adipokines in 3T3-L1 adipocytes. Inflammation. 2009;32(5):296-303.
Andò S, Catalano S. The multifactorial role of leptin in driving the breast cancer microenvironment. Nat Rev Endocrinol. 2011;8(5):263-75.
Andreasen PA. PAI-1 - a potential therapeutic target in cancer.Curr Drug Targets. 2007;8(9):1030-41.
Bajou K, Noël A, Gerard RD, Masson V, Brunner N, Holst-Hansen C, et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med. 1998;4(8):923-8.
Bajou K, Lewalle JM, Martinez CR, Soria C, Lu H, Noël A, et al. Human breast adenocarcinoma cell lines promote angiogenesis by providing cells with uPA-PAI-1 and by enhancing their expression. Int J Cancer. 2002;100(5):501-6.
Baliga MS, Meleth S, Katiyar SK. Growth inhibitory and antimetastatic effect of green tea polyphenols on metastasis-specific mouse mammary carcinoma 4T1 cells in vitro and in vivo systems. Clin Cancer Res. 2005;11(5):1918-27.
Bråkenhielm E, Veitonmäki N, Cao R, Kihara S, Matsuzawa Y, Zhivotovsky B, et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci USA. 2004;101(8):2476-81.
Brodie AE, Manning VA, Ferguson KR, Jewell DE, Hu CY. Conjugated linoleic acid inhibits differentiation of pre- and post- confluent 3T3-L1 preadipocytes but inhibits cell proliferation only in preconfluent cells. J Nutr. 1999;129(3):602-6.
Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625-38.
Cao Y. Angiogenesis modulates adipogenesis and obesity. J Clin Invest. 2007;117(9):2362-8.
Carroll PA, Healy L, Lysaght J, Boyle T, Reynolds JV, Kennedy MJ, et al. Influence of the metabolic syndrome on leptin and leptin receptor in breast cancer. Mol Carcinog. 2011;50(8):643-51.
Carter JC, Church FC. Obesity and breast cancer: the roles of peroxisome proliferator-activated receptor-γ and plasminogen activator inhibitor-1. PPAR Res. 2009;2009:345320.
Catalán V, Gómez-Ambrosi J, Rodríguez A, Frühbeck G. Adipose tissue immunity and cancer. Front Physiol. 2013;4:275.
Catalano S, Mauro L, Marsico S, Giordano C, Rizza P, Rago V, et al. Leptin induces, via ERK1/ERK2 signal, functional activation of estrogen receptor alpha in MCF-7 cells. J Biol Chem. 2004;279(19):19908-15.
Chang HC, Lewis D, Tung CY, Han L, Henriquez SM, Voiles L, et al. Soypeptide lunasin in cytokine immunotherapy for lymphoma. Cancer Immunol Immunother. 2014;63(3):283-95.
Chaudhary A, Sutaria D, Huang Y, Wang J, Prabhu S. Chemoprevention of colon cancer in a rat carcinogenesis model using a novel nanotechnology-based combined treatment system. Cancer Prev Res (Phila). 2011;4(10):1655-64.
Chazaud B, Ricoux R, Christov C, Plonquet A, Gherardi RK, Barlovatz-Meimon G. Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations. Am J Pathol. 2002;160(1):237-46.
Choi EJ, Kim GH. Daidzein causes cell cycle arrest at the G1 and G2/M phases in human breast cancer MCF-7 and MDA-MB-453 cells. Phytomedicine. 2008;15(9):683-90.
Cleary MP, Juneja SC, Phillips FC, Hu X, Grande JP, Maihle NJ. Leptin receptor-deficient MMTV-TGF-alpha/Lepr(db)Lepr(db) female mice do not develop oncogene-induced mammary tumors. Exp Biol Med (Maywood). 2004;229(2):182-93.
Cleary MP, Grossmann ME. Minireview: Obesity and breast cancer: the estrogen connection. Endocrinology. 2009;150(6):2537-42.
Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia. 2003;46(4):459-69.
Cornelius P, MacDougald OA, Lane MD. Regulation of adipocyte development. Annu Rev Nutr. 1994;14:99-129.
Dahners LE, Mullis BH. Effects of nonsteroidal anti-inflammatory drugs on bone formation and soft-tissue healing. J Am Acad Orthop Surg. 2004;12(3):139-43.
Dalamaga M. Obesity, insulin resistance, adipocytokines and breast cancer: New biomarkers and attractive therapeutic targets. World J Exp Med. 2013;3(3):34-42.
Daling JR, Malone KE, Doody DR, Johnson LG, Gralow JR, Porter PL. Relation of body mass index to tumor markers and survival among young women with invasive ductal breast carcinoma. Cancer. 2001;92(4):720-9.
De Pergola G, Silvestris F. Obesity as a major risk factor for cancer. J Obes. 2013;2013:291546.
Dia VP, Gonzalez de Mejia E. Lunasin induces apoptosis and modifies the expression of genes associated with extracellular matrix and cell adhesion in human metastatic colon cancer cells.Mol Nutr Food Res. 2011;55(4):623-34.
Dia VP, Gonzalez de Mejia E. Lunasin potentiates the effect of oxaliplatin preventing outgrowth of colon cancer metastasis, binds to α5β1 integrin and suppresses FAK/ERK/NF-κB signaling. Cancer Lett. 2011;313(2):167-80.
Dia VP, Gonzalez de Mejia E. Potential of lunasin orally-administered in comparison to intraperitoneal injection to inhibit colon cancer metastasis in vivo. J Cancer Ther. 2013;4:34-43.
Dieudonne MN, Bussiere M, Dos Santos E, Leneveu MC, Giudicelli Y, Pecquery R. Adiponectin mediates antiproliferative and apoptotic responses in human MCF7 breast cancer cells. Biochem Biophys Res Commun. 2006;345(1):271-9.
D'Incalci M, Steward WP, Gescher AJ. Use of cancer chemopreventive phytochemicals as antineoplastic agents. Lancet Oncol. 2005;6(11):899-904.
Dirat B, Bochet L, Dabek M, Daviaud D, Dauvillier S, Majed B, et al. Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion. Cancer Res. 2011;71(7):2455-65.
Dovizio M, Bruno A, Tacconelli S, Patrignani P. Mode of action of aspirin as a chemopreventive agent. In: Chan AT, Detering E, editors. Prospects for Chemoprevention of Colorectal Neoplasia. Berlin: Springer-Verlag; 2013. p.39-65.
Dubois V, Delort L, Billard H, Vasson MP, Caldefie-Chezet F. Breast cancer and obesity: in vitro interferences between adipokines and proangiogenic features and/or antitumor therapies? PLoS One. 2013;8(3):e58541.
Dubois V, Jardé T, Delort L, Billard H, Bernard-Gallon D, Berger E, et al. Leptin induces a proliferative response in breast cancer cells but not in normal breast cells. Nutr Cancer. 2014;66(4):645-55.
Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351(9114):1451-67.
Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual. 7th ed. New York: Springer; 2009. p.419-60.
Englund Ogge L, Brohall G, Behre CJ, Schmidt C, Fagerberg B. Alcohol consumption in relation to metabolic regulation, inflammation, and adiponectin in 64-year-old Caucasian women: a population-based study with a focus on impaired glucose regulation. Diabetes Care. 2006;29(4):908-13.
Fernández-Tomé S, Ramos S, Cordero-Herrera I, Recio I, Goya L, Hernández-Ledesma B. In vitro chemo-protective effect of bioactive peptide lunasin against oxidative stress in human HepG2 cells. Food Res Int. 2014;62(1):793-800.
Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005;438(7070):967-74.
Fisher B, Jeong JH, Dignam J, Anderson S, Mamounas E, Wickerham DL, et al. Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer. J Natl Cancer Inst Monogr. 2001;(30):62-6.
Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA. 2010;303(3):235-41.
Ford NA, Lashinger LM, Allott EH, Hursting SD. Mechanistic targets and phytochemical strategies for breaking the obesity-cancer link. Front Oncol. 2013;3:209.
Fox SB, Taylor M, Grøndahl-Hansen J, Kakolyris S, Gatter KC, Harris AL. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer. J Pathol. 2001;195(2):236-43.
Frankenberry KA, Skinner H, Somasundar P, McFadden DW, Vona-Davis LC. Leptin receptor expression and cell signaling in breast cancer. Int J Oncol. 2006;28(4):985-93.
Fritz WA, Coward L, Wang J, Lamartiniere CA. Dietary genistein: perinatal mammary cancer prevention, bioavailability and toxicity testing in the rat. Carcinogenesis. 1998;19(12):2151-8.
Galvez AF, inventor; Galvez AF, assignee. Methods for using soy peptides to inhibit H3 acetylation, reduce expression of HMG-CoA reductase and increase LDL receptor and Sp1 expression in a mammal. United States patent US 7731995. 2008 Jun 8.
Gao Z, Zuberi A, Quon MJ, Dong Z, Ye J. Aspirin inhibits serine phosphorylation of insulin receptor substrate 1 in tumor necrosis factor-treated cells through targeting multiple serine kinases. J Biol Chem. 2003;278(27):24944-50.
García-Nebot MJ, Recio I, Hernández-Ledesma B. Antioxidant activity and protective effects of peptide lunasin against oxidative stress in intestinal Caco-2 cells. Food Chem Toxicol. 2014;65:155-61.
Garofalo C, Surmacz E. Leptin and cancer. J Cell Physiol. 2006;207(1):12-22.
Ghosh N, Chaki R, Mandal V, Mandal SC. COX-2 as a target for cancer chemotherapy. Pharmacol Rep. 2010;62(2):233-44.
Gonzalez RR, Cherfils S, Escobar M, Yoo JH, Carino C, Styer AK, et al. Leptin signaling promotes the growth of mammary tumors and increases the expression of vascular endothelial growth factor (VEGF) and its receptor type two (VEGF-R2). J Biol Chem. 2006;281(36):26320-8.
Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 1999;59(14):3374-8.
Green H, Meuth M. An established pre-adipose cell line and its differentiation in culture. Cell. 1974;3(2):127-33.
Guo S, Gonzalez-Perez RR. Notch, IL-1 and leptin crosstalk outcome (NILCO) is critical for leptin-induced proliferation, migration and VEGF/VEGFR-2 expression in breast cancer. PLoS One. 2011;6(6):e21467.
Hankinson SE1, Colditz GA, Hunter DJ, Manson JE, Willett WC, Stampfer MJ, et al. Reproductive factors and family history of breast cancer in relation to plasma estrogen and prolactin levels in postmenopausal women in the Nurses' Health Study (United States). Cancer Causes Control. 1995;6(3):217-24.
Harmey JH, Bouchier-Hayes D. Vascular endothelial growth factor (VEGF), a survival factor for tumour cells: implications for anti-angiogenic therapy. Bioessays. 2002;24(3):280-3.
Hayashi K, Piras V, Tabata S, Tomita M, Selvarajoo K. A systems biology approach to suppress TNF-induced proinflammatory gene expressions. Cell Commun Signal. 2013;11:84.
Heppner GH, Miller FR, Shekhar PM. Nontransgenic models of breast cancer. Breast Cancer Res. 2000;2(5):331-334.
Herbert JM, Dol F, Bernat A, Falotico R, Lalé A, Savi P. The antiaggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit. Thromb Haemost. 1998;80(3):512-8.
Hernández-Ledesma B, Hsieh CC, de Lumen BO. Lunasin and Bowman-Birk protease inhibitor (BBI) in US commercial soy foods. Food Chem. 2009a;115(2):574-80.
Hernández-Ledesma B, Hsieh CC, de Lumen BO. Antioxidant and anti-inflammatory properties of cancer preventive peptide lunasin in RAW 264.7 macrophages. Biochem Biophys Res Commun. 2009b;390(3):803-8.
Hernández-Ledesma B, Hsieh CC, Dia V, de Mejia EG, de Lumen BO. Lunasin, a cancer preventive seed peptide. In: El-Shemy H, editor. Soybean and health. Rijeka: InTech-open access publisher; 2011. p.145-66.
Hernández-Ledesma B, Hsieh CC, de Lumen BO. Chemopreventive properties of Peptide Lunasin: a review. Protein Pept Lett. 2013;20(4):424-32.
Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura S, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res. 1998;58(17):3761-4.
Hirsh J, Dalen JE, Fuster V, Harker LB, Patrono C, Roth G. Aspirin and other platelet-active drugs. The relationship among dose, effectiveness, and side effects. Chest. 1995;108(4 Suppl):247S-57S.
Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE. Aspirin intake and survival after breast cancer. J Clin Oncol. 2010;28(9):1467-72.
Howe LR, Subbaramaiah K, Brown AM, Dannenberg AJ. Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr Relat Cancer. 2001;8(2):97-114.
Howe LR, Subbaramaiah K, Hudis CA, Dannenberg AJ. Molecular pathways: adipose inflammation as a mediator of obesity-associated cancer. Clin Cancer Res. 2013;19(22):6074-83.
Hsieh CC, Hernández-Ledesma B, de Lumen BO. Soybean peptide lunasin suppresses in vitro and in vivo 7,12-dimethylbenz[a]anthracene-induced tumorigenesis. J Food Sci. 2010a;75(9):H311-6.
Hsieh CC, Hernández-Ledesma B, Jeong HJ, Park JH, de Lumen BO. Complementary roles in cancer prevention: protease inhibitor makes the cancer preventive peptide lunasin bioavailable. PLoS One. 2010b;5(1):e8890.
Hsieh CC, Hernández-Ledesma B, de Lumen BO. Lunasin, a novel seed peptide, sensitizes human breast cancer MDA-MB-231 cells to aspirin-arrested cell cycle and induced apoptosis. Chem Biol Interact. 2010c;186(2):127-34.
Hsieh CC, Hernández-Ledesma B, de Lumen BO. Aspirin and its combinations as new chemopreventive strategies against cancer. In: Demir DM, editor. Aspirin: Therapeutic Uses, Adverse Effects and Pharmacokinetics. New York: Nova Science Publishers; 2011a. p.1-39.
Hsieh CC, Hernández-Ledesma B, de Lumen BO. Lunasin-aspirin combination against NIH/3T3 cells transformation induced by chemical carcinogens. Plant Foods Hum Nutr. 2011b;66(2):107-13.
Hu LX, Du YY, Zhang Y, Pan YY. Synergistic effects of exemestane and aspirin on MCF-7 human breast cancer cells. Asian Pac J Cancer Prev. 2012;13(11):5903-8.
Hull MA, Sandell AC, Montgomery AA, Logan RF, Clifford GM, Rees CJ, et al. A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme (The seAFOod Polyp Prevention Trial): study protocol for a randomized controlled trial. Trials. 2013;14:237.
Iwaki T, Urano T, Umemura K. PAI-1, progress in understanding the clinical problem and its aetiology. Br J Haematol. 2012;157(3):291-8.
Iyengar P, Combs TP, Shah SJ, Gouon-Evans V, Pollard JW, Albanese C, et al. Adipocyte-secreted factors synergistically promote mammary tumorigenesis through induction of anti-apoptotic transcriptional programs and proto-oncogene stabilization. Oncogene. 2003;22(41):6408-23.
Jeong HJ, Jeong JB, Kim DS, Park JH, Lee JB, Kweon DH, et al. The cancer preventive peptide lunasin from wheat inhibits core histone acetylation. Cancer Lett. 2007 Sep 18;255(1):42-8.
Jones G, Srivastava A. Understanding Lunasin's biology and potential as a cancer therapeutic by utilizing Drosophila genetics. Exp Biol Med (Maywood). 2014;239(5):519-28.
Kanai T, Konno H, Tanaka T, Baba M, Matsumoto K, Nakamura S, et al. Anti-tumor and anti-metastatic effects of human-vascular-endothelial- growth-factor-neutralizing antibody on human colon and gastric carcinoma xenotransplanted orthotopically into nude mice. Int J Cancer. 1998;77(6):933-6.
Kang JH, Song KH, Jeong KC, Kim S, Choi C, Lee CH, et al. Involvement of Cox-2 in the metastatic potential of chemotherapy-resistant breast cancer cells. BMC Cancer. 2011;11:334.
Kanthamneni N, Chaudhary A, Wang J, Prabhu S. Nanoparticulate delivery of novel drug combination regimens for the chemoprevention of colon cancer. Int J Oncol. 2010;37(1):177-85.
Kaur P, Nagaraja GM, Zheng H, Gizachew D, Galukande M, Krishnan S, et al. A mouse model for triple-negative breast cancer tumor-initiating cells (TNBC-TICs) exhibits similar aggressive phenotype to the human disease. BMC Cancer. 2012;12:120.
Kim S, Baron JA, Mott LA, Burke CA, Church TR, McKeown-Eyssen GE, et al. Aspirin may be more effective in preventing colorectal adenomas in patients with higher BMI (United States). Cancer Causes Control. 2006;17(10):1299-304.
de Kok TM, van Breda SG, Manson MM. Mechanisms of combined action of different chemopreventive dietary compounds: a review. Eur J Nutr. 2008;47 Suppl 2:51-9.
Kris-Etherton PM, Hecker KD, Bonanome A, Coval SM, Binkoski AE, Hilpert KF, et al. Bioactive compounds in foods: their role in the prevention of cardiovascular disease and cancer. Am J Med. 2002;113 Suppl 9B:71S-88S.
Kumar SS, Radhakrishnan AK, Cheong SK. Immune responses in the microenvironment of a metastatic 4T1 mouse model. Egypt Acad J biology Sci. 2009;2(2):19-26.
Lawlor DA, Davey Smith G, Ebrahim S, Thompson C, Sattar N. Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. J Clin Endocrinol Metab. 2005;90(10):5677-83.
Liu Y, Tamimi RM, Collins LC, Schnitt SJ, Gilmore HL, Connolly JL, et al. The association between vascular endothelial growth factor expression in invasive breast cancer and survival varies with intrinsic subtypes and use of adjuvant systemic therapy: results from the Nurses' Health Study. Breast Cancer Res Treat. 2011;129(1):175-84.
Lorincz AM, Sukumar S. Molecular links between obesity and breast cancer. Endocr Relat Cancer. 2006;13(2):279-92.
Luo YP, Zhou H, Krueger J, Kaplan C, Liao D, Markowitz D, et al. The role of proto-oncogene Fra-1 in remodeling the tumor microenvironment in support of breast tumor cell invasion and progression. Oncogene. 2010;29(5):662-73.
Macciò A, Madeddu C, Mantovani G. Adipose tissue as target organ in the treatment of hormone-dependent breast cancer: new therapeutic perspectives. Obes Rev. 2009;10(6):660-70.
Maughan KL, Lutterbie MA, Ham PS. Treaement of breast cancer. Am Fam Physician. 2010;81(11):1339-46.
Mazid MA, Chowdhury AA, Nagao K, Nishimura K, Jisaka M, Nagaya T, et al. Endogenous 15-deoxy-Delta(12,14)-prostaglandin J(2) synthesized by adipocytes during maturation phase contributes to upregulation of fat storage. FEBS Lett. 2006;580(30):6885-90.
McMahon G. VEGF receptor signaling in tumor angiogenesis. Oncologist. 2000;5 Suppl 1:3-10.
de Mejia EG, Dia VP. Lunasin and lunasin-like peptides inhibit inflammation through suppression of NF-kappaB pathway in the macrophage. Peptides. 2009;30(12):2388-98.
Menzel T1, Schauber J, Kreth F, Kudlich T, Melcher R, Gostner A, et al. Butyrate and aspirin in combination have an enhanced effect on apoptosis in human colorectal cancer cells. Eur J Cancer Prev. 2002;11(3):271-81.
Moreno-Navarrete JM, Fernández-Real JM. Adipocyte differentiation. In: Symonds ME, editor. Adipose tissue biology. New York: Springer-Verlag; 2011. p.17-38.
Murakami A, Takahashi D, Hagihara K, Koshimizu K, Ohigashi H. Combinatorial effects of nonsteroidal anti-inflammatory drugs and food constituents on production of prostaglandin E2 and tumor necrosis factor-alpha in RAW264.7 murine macrophages. Biosci Biotechnol Biochem. 2003;67(5):1056-62.
Nair S, Al-Hendy A. Adipocytes enhance the proliferation of human leiomyoma cells via TNF-α proinflammatory cytokine. Reprod Sci. 2011;18(12):1186-92.
Nalabolu MR, Palasamudram K, Jamil K. Adiponectin and leptin molecular actions and clinical significance in breast cancer. Int J Hematol Oncol Stem Cell Res. 2014;8(1):31-40.
Newman G, Gonzalez-Perez RR. Leptin-cytokine crosstalk in breast cancer. Mol Cell Endocrinol. 2014;382(1):570-82.
Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014 Aug 30;384(9945):766-81.
Nkhata KJ, Ray A, Schuster TF, Grossmann ME, Cleary MP. Effects of adiponectin and leptin co-treatment on human breast cancer cell growth. Oncol Rep. 2009;21(6):1611-9.
Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol. 2010;72:219-46.
O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med. 1996;2(6):689-92.
Ozsaran Z, Alanyalı SD. Staging of Breast Cancer. In: Haydaroglu A, Ozyigit G, editors. Principles and Practice of Modern Radiotherapy Techniques in Breast Cancer. New York: Springer-Verlag; 2013. p.13-9.
Park JHY, Kang YH, Sung MK, Kwon DY, Yang Y. Diet-Induced Obesity, Inflammation, and Cancer. J Food Drug Anal. 2012;20 Suppl 1:237-40.
Peterson G, Barnes S. Genistein inhibition of the growth of human breast cancer cells: independence from estrogen receptors and the multi-drug resistance gene. Biochem Biophys Res Commun. 1991;179(1):661-7.
Pidgeon GP, Barr MP, Harmey JH, Foley DA, Bouchier-Hayes DJ. Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells. Br J Cancer. 2001;85(2):273-8.
Purohit A, Newman SP, Reed MJ. The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer. Breast Cancer Res. 2002;4(2):65-9.
Ramos-Nino ME. The role of chronic inflammation in obesity-associated cancers. ISRN Oncol. 2013;2013:697521.
Ray A, Nkhata KJ, Cleary MP. Effects of leptin on human breast cancer cell lines in relationship to estrogen receptor and HER2 status. Int J Oncol. 2007;30(6):1499-509.
Roland CL, Lynn KD, Toombs JE, Dineen SP, Udugamasooriya DG, Brekken RA. Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer. PLoS One. 2009;4(11):e7669.
Rolka DB, Fagot-Campagna A, Narayan KM. Aspirin use among adults with diabetes: estimates from the Third National Health and Nutrition Examination Survey. Diabetes Care. 2001;24(2):197-201.
Ron D, Brasier AR, McGehee RE Jr, Habener JF. Tumor necrosis factor-induced reversal of adipocytic phenotype of 3T3-L1 cells is preceded by a loss of nuclear CCAAT/enhancer binding protein (C/EBP). J Clin Invest. 1992;89(1):223-33.
Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 2012;379(9826):1591-601.
Russo M, Tedesco I, Iacomino G, Palumbo R, Galano G, Russo GL. Dietary phytochemicals in chemoprevention of cancer. Curr Med Chem Immunol Endocr Metab Agents. 2005;5(1):61-72.
Russo M, Spagnuolo C, Tedesco I, Russo GL. Phytochemicals in cancer prevention and therapy: truth or dare? Toxins (Basel). 2010;2(4):517-51.
Sakamoto K, Sakamoto T, Ogawa H. Effects of metabolic risk factors on production of plasminogen activator inhibitor-1 and adiponectin by adipocytes. Circ J. 2008;72(5):844-6.
Sarkar FH, Li Y. Mechanisms of cancer chemoprevention by soy isoflavone genistein. Cancer Metastasis Rev. 2002;21(3-4):265-80.
Saxena NK, Sharma D. Multifaceted leptin network: the molecular connection between obesity and breast cancer. J Mammary Gland Biol Neoplasia. 2013 Dec;18(3-4):309-20.
Shapiro CL, Recht A. Side effects of adjuvant treatment of breast cancer. N Engl J Med. 2001;344(26):1997-2008.
Sharpe CR, Collet JP, McNutt M, Belzile E, Boivin JF, Hanley JA. Nested case-control study of the effects of non-steroidal anti-inflammatory drugs on breast cancer risk and stage. Br J Cancer. 2000;83(1):112-20.
Shibata A, Nagaya T, Imai T, Funahashi H, Nakao A, Seo H. Inhibition of NF-kappaB activity decreases the VEGF mRNA expression in MDA-MB-231 breast cancer cells. Breast Cancer Res Treat. 2002;73(3):237-43.
Shtivelband MI, Juneja HS, Lee S, Wu KK. Aspirin and salicylate inhibit colon cancer medium- and VEGF-induced endothelial tube formation: correlation with suppression of cyclooxygenase-2 expression. J Thromb Haemost. 2003;1(10):2225-33.
Singh M, Jangra B. Association between body mass index and risk of breast cancer among females of north India. South Asian J Cancer. 2013;2(3):121-5.
Sjöström L, Gummesson A, Sjöström CD, Narbro K, Peltonen M, Wedel H, et al. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol. 2009;10(7):653-62.
Soma D, Kitayama J, Yamashita H, Miyato H, Ishikawa M, Nagawa H. Leptin augments proliferation of breast cancer cells via transactivation of HER2. J Surg Res. 2008;149(1):9-14.
Somasundar P, Yu AK, Vona-Davis L, McFadden DW. Differential effects of leptin on cancer in vitro. J Surg Res. 2003;113(1):50-5.
Sporn MB. Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res. 1976;36(7 PT 2):2699-702.
Su YF, Yang SH, Lee YH, Wu BC, Huang SC, Liu CM, et al. Aspirin-induced inhibition of adipogenesis was p53-dependent and associated with inactivation of pentose phosphate pathway. Eur J Pharmacol. 2014;738:101-10.
Subbaramaiah K, Telang N, Ramonetti JT, Araki R, DeVito B, Weksler BB, et al. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res. 1996;56(19):4424-9.
Subbegowda R, Frommel TO. Aspirin toxicity for human colonic tumor cells results from necrosis and is accompanied by cell cycle arrest. Cancer Res. 1998;58(13):2772-6.
Suganami T, Nishida J, Ogawa Y. A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. Arterioscler Thromb Vasc Biol. 2005;25(10):2062-8.
Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer. 2003;3(10):768-80.
Surmacz E. Leptin and adiponectin: emerging therapeutic targets in breast cancer. J Mammary Gland Biol Neoplasia. 2013;18(3-4):321-32.
Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J Natl Cancer Inst. 1998;90(21):1609-20.
Tao K, Fang M, Alroy J, Sahagian GG. Imagable 4T1 model for the study of late stage breast cancer. BMC Cancer. 2008;8:228.
Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr. Aspirin use and risk of fatal cancer. Cancer Res. 1993;53(6):1322-7.
Toomey DP, Murphy JF, Conlon KC. COX-2, VEGF and tumour angiogenesis. Surgeon. 2009;7(3):174-80.
Torii T, Miyamoto Y, Sanbe A, Nishimura K, Yamauchi J, Tanoue A. Cytohesin-2/ARNO, through its interaction with focal adhesion adaptor protein paxillin, regulates preadipocyte migration via the downstream activation of Arf6. J Biol Chem. 2010;285(31):24270-81.
Tsao AS, Kim ES, Hong WK. Chemoprevention of cancer. CA Cancer J Clin. 2004;54(3):150-80.
Vaiopoulos AG, Marinou K, Christodoulides C, Koutsilieris M. The role of adiponectin in human vascular physiology. Int J Cardiol. 2012;155(2):188-93.
van den Brandt PA, Spiegelman D, Yaun SS, Adami HO, Beeson L, Folsom AR, et al. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol. 2000;152(6):514-27.
Vona-Davis L, Rose DP. Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr Relat Cancer. 2007;14(2):189-206.
Wang Y, Lam JB, Lam KS, Liu J, Lam MC, Hoo RL, et al. Adiponectin modulates the glycogen synthase kinase-3beta/beta-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice. Cancer Res. 2006;66(23):11462-70.
World Health Organization. Breast cancer: prevention and control. 2014.
Xiao CW. Health effects of soy protein and isoflavones in humans. J Nutr. 2008;138(6):1244S-9S.
Yuan HJ, Sun KW, Yu K. Leptin promotes the proliferation and migration of human breast cancer through the extracellular-signal regulated kinase pathway. Mol Med Rep. 2014;9(1):350-4.
Zhang X1, Tian W, Cai X, Wang X, Dang W, Tang H, et al. Hydrazinocurcumin Encapsuled nanoparticles "re-educate" tumor-associated macrophages and exhibit anti-tumor effects on breast cancer following STAT3 suppression. PLoS One. 2013;8(6):e65896.
Zhou W, Guo S, Gonzalez-Perez RR. Leptin pro-angiogenic signature in breast cancer is linked to IL-1 signalling. Br J Cancer. 2011;104(1):128-37.
Zhu J, Yong W, Wu X, Yu Y, Lv J, Liu C, et al. Anti-inflammatory effect of resveratrol on TNF-alpha-induced MCP-1 expression in adipocytes. Biochem Biophys Res Commun. 2008;369(2):471-7.

下載圖示
QR CODE